rosuvastatin (Crestor)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Crestor. FDA approves generics 4/16[10][13].

Public Citizen pushed the FDA to take rosuvastatin (Crestor) off the market (2004)[2]; labeled a 'dangerous drug'[5]

Indications

Contraindications

pregnancy category = x

Dosage

Dosage adjustment in renal failure

Pharmacokinetics

elimination by hemodialysis = -

Monitor

* no substantial reason given except for assessment of medication compliance; no suggestion given how results of testing would =change management[12]

Adverse effects

Toxicity:

Drug interactions

Mechanism of action

Notes

More general terms

Additional terms

Component of

References

  1. Prescriber's Letter 10(8):43 2003
  2. 2.0 2.1 Prescriber's Letter 11(4):19-20 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200402&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. 3.0 3.1 FDA Medwatch http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#crestor
  4. 4.0 4.1 4.2 4.3 4.4 Prescriber's Letter 12(4): 2005 FDA Public Health Advisory on Crestor (rosuvastatin) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210402&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. 5.0 5.1 Prescriber's Letter 12(7): 2005 The Safety of Crestor (Rosuvastatin) - An Update Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210703&pb=PRL (subscription needed) http://www.prescribersletter.com
  6. Prescriber's Letter 15(12): 2008 COMMENTARY: Rosuvastatin (Crestor) for High C-Reactive Protein GUIDELINES: National Cholesterol Education Program (NCEP) Recommendations GUIDELINES: Markers of Inflammation and Cardiovascular Disease GUIDELINES: Canadian Cardiovascular Society Position Statement- Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=241201&pb=PRL (subscription needed) http://www.prescribersletter.com
  7. Prescriber's Letter 17(3): 2010 Rosuvastatin (Crestor) for High C-Reactive Protein (CRP) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260302&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. 8.0 8.1 AstraZeneca announces top-line results from SATURN study http://www.astrazeneca.com/Media/Press-releases/Article/02092011-astrazeneca-saturn-study-results
  9. 9.0 9.1 Nicholls SJ et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011 Nov 15 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22085316 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1110874
  10. 10.0 10.1 Stiles S FDA Approves Generic Rosuvastatin (Crestor) Medscpape. April 29, 2016 http://www.medscape.com/viewarticle/862674
    FDA News Release. April 29, 2016. FDA approves first generic Crestor. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498373.htm
  11. 11.0 11.1 Zheng Z, Jayaram R, Jiang J et al Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med 2016; 374:1744-1753. May 5, 2016 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27144849
  12. 12.0 12.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  13. 13.0 13.1 NEJM Editors FDA Approves Additional Generic Versions of Rosuvastatin Physician's First Watch, July 21, 2016 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
  14. 14.0 14.1 14.2 14.3 14.4 14.5 14.6 14.7 Wiggins BS, Saseen JJ, Page RL 2nd et al Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease. A Scientific Statement From the American Heart Association. Circulation. 2016;134:00-00 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27754879 <Internet> http://circ.ahajournals.org/content/circulationaha/early/2016/10/17/CIR.0000000000000456.full.pdf
  15. 15.0 15.1 Brailovski E et al Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. Aug 4, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32744865 https://www.acpjournals.org/doi/10.7326/L20-0549
  16. 16.0 16.1 Busko M Rosuvastatin Again Linked With Risks to Kidneys Medscape. July 20, 2022 https://www.medscape.com/viewarticle/977646
    Shin JI, Fine DM, Sang Y et al Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria. J Am Soc Nephrol (JASN) July 2022, ASN.2022020135 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35853713 https://jasn.asnjournals.org/content/early/2022/07/19/ASN.2022020135
  17. 17.0 17.1 Windle ML Rapid Rx Quiz: Statin Intolerance and Related Concerns Medscape. September 01, 2022 https://reference.medscape.com/viewarticle/979515
  18. 18.0 18.1 Lee YJ et al. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: Secondary analysis of the randomised LODESTAR trial. BMJ 2023 Oct 18; 383:e075837. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37852649 PMCID: PMC10583134 Free PMC article https://www.bmj.com/content/383/bmj-2023-075837
  19. http://www.crestor.com

Database